Outcome of the Board Meeting held on 4 February 2026 - Unaudited Standalone Financial Results of the Company for the third quarter and nine months ended 31 December 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Gujarat Terce Laboratories approved the unaudited standalone financial results for Q3FY26 (quarter ended 31 December 2025) and the nine months ended 31 December 2025. Revenue from operations for Q3FY26 stood at Rs 12,303.5 lakhs versus Rs 12,680.8 lakhs in Q3FY25, a YoY decline of about 3%. For the nine-month period, revenue was Rs 36,073.4 lakhs vs Rs 37,870.8 lakhs last year, down roughly 4.75%. Profit after tax for Q3FY26 fell to Rs 761.1 lakhs from Rs 1,008 lakhs a year ago, while 9M PAT came in at Rs 2,110.5 lakhs versus Rs 2,412.6 lakhs. Importantly, FY25 had been a loss-making year for the company, so FY26 results reflect a return to profitability. The statutory auditor Shah Doshi Patel & Associates LLP issued an unmodified limited review report.
Both top-line and bottom-line shrank on a year-on-year basis in Q3FY26, which could weigh on short-term investor sentiment. However, the company has moved back into profit territory after the FY25 loss, so the overall trajectory is one of recovery rather than deterioration.